Talphera (TLPH) Income from Continuing Operations (2010 - 2026)
Talphera's (TLPH) quarterly Income from Continuing Operations came in at 3897000.0 in Q1 2026, down 36.88% year-on-year from 6174045.08 in Q1 2025, and down 3.4% quarter-over-quarter from 3769000.0 in Q4 2025.
Talphera (TLPH) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Talphera's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 3897000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 36.88% year-over-year to 3897000.0 in Q1 2026; TTM through Mar 2026 was 14843000.0, a 13.13% decrease from a year earlier, with the FY2025 full-year figure at 85535000.0, up 27.23% from the prior year.
- Income from Continuing Operations declined to 3897000.0 in Q1 2026 per TLPH's latest filing, from 3769000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 74315000.0 in Q2 2022 and bottomed at 15954000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 3769000.0 (2025), against an average of 46470.59.
- Biggest YoY gain for Income from Continuing Operations was 854.39% in 2022; the steepest drop was 2843.54% in 2022.
- Year by year, Income from Continuing Operations stood at 15954000.0 in 2022, then surged by 56.12% to 7000000.0 in 2023, then jumped by 55.81% to 3093000.0 in 2024, then retreated by 21.86% to 3769000.0 in 2025, then decreased by 3.4% to 3897000.0 in 2026.
- Per Business Quant, the three latest TLPH Income from Continuing Operations figures stand at 3897000.0 (Q1 2026), 3769000.0 (Q4 2025), and 3567000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.90 Mn |
| Dec 31, 2025 | -3.77 Mn |
| Sep 30, 2025 | -3.57 Mn |
| Jun 30, 2025 | -3.61 Mn |
| Mar 31, 2025 | -2.85 Mn |
| Dec 31, 2024 | -3.09 Mn |
| Sep 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.83 Mn |
| Mar 31, 2024 | -4.02 Mn |
| Dec 31, 2023 | -7.00 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | -329,000.00 |
| Dec 31, 2022 | -15.95 Mn |
| Sep 30, 2022 | -4.64 Mn |
| Jun 30, 2022 | 74.32 Mn |
| Mar 31, 2022 | -9.36 Mn |
| Dec 31, 2021 | -542,000.00 |
| Sep 30, 2021 | -8.38 Mn |
| Jun 30, 2021 | -9.85 Mn |